Company news

Roche Holding Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue

October 29, 2025

Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome

October 28, 2025

Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

October 27, 2025

Changes to the Roche Enlarged Corporate Executive Committee

October 23, 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

October 23, 2025

Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment

October 20, 2025

FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

October 20, 2025

Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

October 18, 2025

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

October 17, 2025

CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis

October 17, 2025

Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025

October 16, 2025

Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology

October 13, 2025

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

October 13, 2025

Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub

October 10, 2025

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care

October 7, 2025

Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel

October 6, 2025

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

October 3, 2025

Change in the Roche Board of Directors

October 3, 2025

FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

October 2, 2025

Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

October 1, 2025

Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks

September 30, 2025

Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025

September 24, 2025

Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

September 22, 2025

CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

September 19, 2025

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

September 18, 2025

89bio, Inc. Announces Agreement to be Acquired by Roche

September 16, 2025

Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience

September 16, 2025

New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)

September 5, 2025

Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)

September 4, 2025

← Newer news releases

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 261 decks. Every deck is listed under its year.